An interventional study of Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER) and Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER) in Alzheimer's Dementia (AD), sponsored by University of Strathclyde. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by University of Strathclyde · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies in Dementia with a site in United Kingdom — 39 open to participants now, 58 under way, 12 of them phase 3. Dementia · United Kingdom.
Among the 178 studies in Dementia with a site in United Kingdom, this one is the 100th largest by planned enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 56 with no phase, reaches primary completion later than 15 of the 57 other live ones, and was the 158th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →39 of the 178 studies in Dementia with a site in United Kingdom are open now. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 55+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 55–90
Northumbria Healthcare NHS Foundation Trust · Sites in United Kingdom
Ages 65+
Exciva GmbH · Sites in United Kingdom, United States, Canada and 6 more countries
Ages 55–90
University of Nottingham · Sites in United Kingdom
Ages 18–99 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 34 · Phase 3 40 · Phase 4 3
First in 1999; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 196 across the 124 interventional studies, 210 across the 54 observational. Of the 94 that completed or were terminated, 27 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 178 have an industry lead sponsor. The 10 most frequent:
University of Strathclyde is the lead sponsor of 20 studies on the registry; 10 are open to participants now.
University of Strathclyde has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
9 of the studies in Dementia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07347431Northumbria Healthcare NHS Foundation TrustLarge Language Model for Understanding and Monitoring Elderly Neurocognition | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT06263920Lancashire Teaching Hospitals NHS Foundation TrustNeurofrailty: A Study of Late-onset Epilepsy and Its Associations | 2027-01-12 |
| NCT06937541University of West LondonFamily Interventions iN Dementia Mental Health Environments | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 178 studies in Dementia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The AMPER (Agent-based Memory Prosthesis to Encourage Reminiscing) system has been built to help people with Alzheimer's disease by improving their memory recall and quality of life. Alzheimer's often leads to the loss of autobiographical memories, which can affect a person's sense of identity. AMPER seeks to address this by creating a digital memory aid that uses an engaging, animated character on a tablet to help individuals with Alzheimer's reminisce about their past. By presenting personally relevant stories, images, audio, and videos, the character helps trigger memories and encourages interaction with caregivers.
This is proof of concept study using a randomised controlled trial methodology. Twenty participants will be randomised to the control and 20 randomised to the intervention condition. The intervention group will use a personalised version of the AMPER app with tailored content and the control group will use a non-personalised version without specific adaptations. Over 12 weeks, participants will use the app at home with their caregivers. Researchers will measure changes in their memory and cognitive abilities before and after these 12 weeks.
The primary goal is to see if personalised reminiscence improves the perceived quality of the reminiscence experience and autobiographical memory ability compared to the same app with a non-personalised approach. This will be measured using a combination of automatically gathered app use data and weekly caregiver feedback. Secondary goals are to investigate any difference between participants in the intervention and control condition in their technology acceptance, quality of life, self-esteem, everyday functioning and cognitive ability.
Feedback from this research will help refine AMPER and inform future studies, with the ultimate goal of creating a widely accessible tool that supports memory and well-being in Alzheimer's patients. Table 1 provides a summary of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AMPER app will be provided on a tablet, used with a caregiver in the participant's home for 12 weeks, at least twice a week AND the app will cater topic 'stories' (content) to the persons pre-stated preferences and provide content from the decades that correspond to the person's reminiscence 'bump' (when they were between 10 and 30 years old).
Device: Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)
AMPER app will be provided on a tablet, used with a caregiver in the participant's home for 12 weeks, at least twice a week. AND the app will provide random content not linked to persons preferences or age.
Device: Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)
AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Personalised AMPER is personalised to preferences and age of the participant.
AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Non-personliased AMPER is not personalised to preferences or age of the participant.
Quality of autobiographical memory during AMPER use
We will analyse the richness of episodic and semantic details in the participant's recollections (which are audio recorded during the trial). This method will ensure a systematic evaluation of memory quality during interactions facilitated by the AMPER app. This rating procedure will use the methodology outlined by Levine and colleagues (2002) and will be scored using the semi-automated methodology outlined by Wardell and colleagues (2021).
Time frame: From enrollment to the end of AMPER use at 12 weeks
Autobiographical Memory ability (objectively rated)
Objective rating of Autobiographical Memory ability using the Autobiographical Memory Interview (Kopelman et al., 1989)
Time frame: Baseline (week 1) and follow up (week 14)
Autobiographical Memory ability (subjectively rated)
Autobiographical memory ability will be subjectively rated using the Autobiographical Recollection Test (ART), (Berntsen et al., 2019).
Time frame: Baseline (week 1) and follow up (week 14)
Autobiographical Memory ability (subjectively rated on SAM)
Autobiographical memory ability will also be subjectively rated using the survey of Autobiographical memory (SAM), (Palombo et al., 2012)
Time frame: Baseline (week 1) and follow up (week 14)
Functional ability in tasks of everyday living
Instrumental Activities of Daily Living (IADL), (Lawton \& Brody, 1969)
Time frame: Baseline (week 1) and follow up (week 14)
Quality of life for the individual with Alzheimer's disease (subjective)
Quality of life Alzheimer's Disease (Logsdon et al., 1999)
Time frame: Baseline (week 1) and follow up (week 14)
Level of Depression experienced by the person with AD (subjective)
Geriatric Depression Scale (GDS), (Yesavage et al., 1982),
Time frame: Baseline (week 1) and follow up (week 14)
Cognitive ability of the person with AD
Addenbrooke's Cognitive Examination ACE-III (Mioshi et al., 2006)
Time frame: Baseline (week 1) and follow up (week 14)
Verbal learning ability for the person with AD
Hopkins Verbal Learning Test (HVLT) (Benedict et al., 1998)
Time frame: Baseline (week 1) and follow up (week 14)
Short term verbal memory for person with AD
Digit Span forwards and backwards from the Wechsler Adult Intelligence Scale (4th edition), (Wechsler, 2008)
Time frame: Baseline (week 1) and follow up (week 14)
Executive functioning for person with AD
Trail Making Test (Reitan, \& Wolfson, 1985)
Time frame: Baseline (week 1) and follow up (week 14)
Modified Hachinski Ischemia Scale score for person with AD
Modified Hachinski Ischemia Scale (mHIS) (Hachinski et al., 2012)
Time frame: Baseline (week 1) and follow up (week 14)
Self-esteem for the person with AD
The Rosenberg Self Esteem scale (Rosenberg, 1965)
Time frame: Baseline (week 1) and follow up (week 14)
Technology acceptance for person with AD
The ALMERE questionnaire (Heerink et al., 2010).
Time frame: Baseline (week 1) and follow up (week 14)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Feb 2026, 10 months later.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 10 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Strathclyde